Development of novel In-vitro and In-vivo Models to support NeuroHIV Research
ID: NIH/NIMH 002Type: BOTH
Overview

Topic

Development of novel In-vitro and In-vivo Models to support NeuroHIV Research

Agency

Department of Health and Human ServicesNational Institutes of Health

Program

Type: SBIRPhase: BOTHYear: 2023

Topic Link

https://www.sbir.gov/node/2451757

Additional Information

https://sam.gov/opp/aa72581c848947f0b61c15062e604862/view
Timeline
  1. 1
    Release Aug 25, 2023 12:00 AM
  2. 2
    Open Aug 25, 2023 12:00 AM
  3. 3
    Next Submission Due Nov 14, 2023 12:00 AM
  4. 4
    Close Nov 14, 2023 12:00 AM
Description

The Department of Health and Human Services, specifically the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC), are seeking proposals for Small Business Innovation Research (SBIR) contract proposals. The specific topic of the solicitation is the development of novel In-vitro and In-vivo models to support NeuroHIV research. The goal of this research is to better understand the Immune-Central Nervous System (CNS) interactions in the context of HIV. The solicitation is open to both Phase I and Phase II proposals, with a total of 1-3 anticipated awards. The budget for Phase I is $300,000 for up to 1 year, and for Phase II it is $2,000,000 for up to 2 years. The deadline for proposal submission is November 14, 2023. For more information and to access the solicitation, visit the provided links.

Files
No associated files provided.
Similar Opportunities
NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required). This solicitation encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials, including mechanistic studies associated with clinical trials. The program supports milestone-driven, hypothesis-driven clinical trials related to the research mission of the NIAID that address high-priority research areas. The solicitation encourages high-risk clinical studies, which involve non-routine interventions, administration of unlicensed products, or administration of licensed products for unapproved indications. Mechanistic studies are also encouraged. The funding supports the conduct, completion, and analysis of a single clinical trial, including activities such as training of study personnel, enrollment and recruitment of study subjects, data collection and management, laboratory work, study management and oversight, safety monitoring, and regulatory activities. The project duration is not specified, but the solicitation is open until January 14, 2027. The funding specifics can be found on the grants.nih.gov website.
NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required) topic. This solicitation aims to support small business concerns (SBCs) in conducting exploratory clinical trials that contribute to the justification for future trials to establish definitive efficacy. The trials can include Phase 1 and 2 studies of drugs and biologics, feasibility and preliminary efficacy studies of devices, as well as early studies of surgical, behavioral, or rehabilitation therapies. The trials can be single-site or multi-site with up to three clinical sites. The applications must generate data that inform further clinical development of the proposed intervention or diagnostic, and FDA approval is required for FDA-regulated clinical trials. The goal is to advance products/technologies that require federal regulatory approval or bring complex research tools to market. The solicitation is open until September 6, 2026, and more information can be found at the provided links.
Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for advancing research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) through their Small Business Innovation Research (SBIR) program. The goal of this funding opportunity is to encourage research and commercialization of novel therapies, devices, products, and healthcare programs to prevent the onset of AD/ADRD and reduce the burden on individuals, families, and society. The research areas of interest include prevention, diagnosis, treatment, care, tools, and technology. Examples of specific topics include behavioral interventions, diagnostic screening tests, drug development, in-home technologies, and tools for monitoring cognitive function. The solicitation is open until September 8, 2025, with multiple application due dates throughout the year. More information can be found on the grants.gov website.
NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required). This solicitation aims to support small business concerns (SBCs) in conducting exploratory clinical trials that contribute to the justification for future trials to establish definitive efficacy. The trials can include Phase 1 and 2 studies of drugs and biologics, feasibility and preliminary efficacy studies of devices, as well as early studies of surgical, behavioral, or rehabilitation therapies. The trials can be single-site or multi-site with up to three clinical sites. The applications must generate data that inform further clinical development of the proposed intervention or diagnostic, and FDA approval is required for FDA-regulated clinical trials. The goal is to advance products/technologies that require federal regulatory approval or bring complex research tools to market. The funding opportunity is open until September 6, 2026. For more information and to apply, visit the solicitation agency URL: [link](https://grants.nih.gov/grants/guide/pa-files/PAR-24-044.html).
NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required). This solicitation aims to support small business concerns (SBCs) in conducting exploratory clinical trials that contribute to the justification for future trials to establish definitive efficacy. The trials can include Phase 1 and 2 studies of drugs and biologics, feasibility and preliminary efficacy studies of devices, as well as early studies of surgical, behavioral, or rehabilitation therapies. The trials can be single-site or multi-site with up to three clinical sites. The applications must generate data that inform further clinical development of the proposed intervention or diagnostic, and FDA approval is required for FDA-regulated clinical trials. The goal is to advance products/technologies that require federal regulatory approval or bring complex research tools to market. The funding opportunity is open until September 6, 2026. For more information and to apply, visit the solicitation agency URL: [link](https://grants.nih.gov/grants/guide/pa-files/PAR-24-044.html).